Forbes - - PROMOTION - Ed­i­tor in Chief Paul Trust­full

The World Health Or­ga­ni­za­tion pro­jects that the num­ber of new cases of di­a­betes and cancer in Latin Amer­ica could in­crease by more than 70% in the next decade. Pre­vent­ing and com­bat­ting these dis­eases re­quires in­no­va­tion and in­vest­ment. The Mex­i­can com­pany Nanophar­ma­cia Group of­fers both.

The com­pany is ris­ing to the chal­lenges of health care in Mex­ico and Latin Amer­ica. It is the only pri­vate com­pany in Latin Amer­ica in the busi­ness of devel­op­ing new ther­a­peu­tic prod­ucts us­ing nan­otech­nol­ogy to treat di­a­betes and cancer.

“Di­a­betes is a metabolic dis­ease that has in­creased dra­mat­i­cally in Mex­ico in the last 10 years, and cancer is a com­plex dis­ease closely linked to multiple fac­tors in­clud­ing metabolic and in­fec­tious,” says Ho­ra­cio As­tudillo de la Vega, Nanophar­ma­cia lead sci­en­tist, founder and part­ner.

Nanophar­ma­cia Group in­te­grates Nanophar­ma­cia Di­ag­nos­tica, a leader in pre­ci­sion cancer medicine in Mex­ico; Nan­oclinic, a clin­i­cal lab­o­ra­tory di­ag­nos­tic firm; Health­care Busi­ness and Com­puter Tech­nolo­gies, which of­fers novel sup­ple­ment com­bi­na­tions and med­i­cal de­vice tech­nolo­gies; and DNI Ge­net­ics & Nutri­tion, de­vel­oper of ge­netic me­tab­o­lism di­ag­nos­tics and per­son­al­ized nu­tri­tional treat­ments. Each com­pany is al­ready ac­tive com­mer­cially with prod­ucts and ser­vices, us­ing 100% Mex­i­canowned sci­en­tific de­vel­op­ments.

Nanophar­ma­cia Group has eval­u­ated more than 40,000 cases in the last eight years and serves pa­tients with chronic de­gen­er­a­tive dis­eases at both public and pri­vate in­sti­tu­tions. Its pri­vate Nanophar­ma­cia Foun­da­tion was es­tab­lished to fur­ther pro­vide re­search and sup­port for dis­ease pre­ven­tion and cures.

Im­prov­ing Lives With De­tec­tion and Ad­vanced Treat­ments

“In Mex­ico, a na­tional pro­gram for timely de­tec­tion has not been es­tab­lished,” says As­tudillo de la Vega. “Di­a­betes treat­ment and de­tec­tion strate­gies have not had a fa­vor­able im­pact on dis­ease con­trol in our coun­try. In Latin Amer­ica, the sit­u­a­tion is no less se­ri­ous, as in Mex­ico, the high cost of med­i­cal and phar­ma­ceu­ti­cal in­ter­ven­tions is not ac­ces­si­ble to the en­tire pop­u­la­tion.” By of­fer­ing ad­vanced early-de­tec­tion and di­ag­nos­tic tools, Nanophar­ma­cia hopes to im­prove lives.

As it con­tin­ues to in­no­vate, the com­pany is look­ing to ex­pand the mar­ket for its sup­ple­ment prod­ucts. Some of these for­mu­la­tions, im­proved with the use of nan­otech­nol­ogy, have been proven ben­e­fi­cial for reg­u­lat­ing the metabolic be­hav­ior of com­plex dis­eases such as di­a­betes and cancer. Some of Nanophar­ma­cia’s sup­ple­ment for­mu­la­tions have been granted patents in the United States, the EU and in more than 40 coun­tries in­clud­ing China, In­dia and Rus­sia. Many more are in the pipe­line.

Nanophar­ma­cia’s prod­uct DIAKRONE de­vel­oped by Nanophar­ma­cia has demon­strated ben­e­fits for pa­tients with di­a­betes and di­a­betic com­pli­ca­tions. DIAKRONE was ap­proved by Mex­ico’s health and drug reg­u­la­tory agency COFEPRIS to start the first study with di­a­betic pa­tients, a step to­ward the prod­uct’s ap­proval.

“The global mar­ket for ad­vanced molec­u­lar di­ag­no­sis and sup­ple­ments is one of the fastest grow­ing in the world,” says As­tudillo de la Vega. “It is es­ti­mated that it will reach more than $16 bil­lion by 2025, es­pe­cially for prod­ucts that of­fer com­bi­na­tions with im­proved ef­fi­cacy based on the use of nan­otech­nol­ogy as we are do­ing now. This seg­ment of devel­op­ment in phar­ma­ceu­ti­cal and sci­en­tific in­no­va­tion is un­doubt­edly the one with the great­est ac­cel­er­a­tion in in­vest­ment for new busi­nesses.”

Nanophar­ma­cia Lab­o­ra­tory Ma­chine

Ho­ra­cio As­tudillo de la Vega, Nanophar­ma­cia lead sci­en­tist, founder and part­ner

Paul Trust­full and Ho­ra­cio As­tudillo de la Vega

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.